Biogaia Enters Into Agreements For New Indication Area

Chr. Hansen A/S the Danish Food ingredient company, Urex Biotech Inc. a Canadian research company and BioGaia the Swedish probiotic company have entered agreements that will allow the global distribution of a probiotic product containing a strain of Lactobacillus reuteri targeting women. The basis for the product is the clinical research performed by Urex, the product development of Chr. Hansen and now the combined distribution capacity of both Chr Hansen and BioGaia.

The product is the world's first clinically documented oral probiotic product concept for restoring and maintaing a healthy vaginal flora. Maintaining a healthy vaginal flora may diminish the risk of acquiring urogenital infections such as bacterial vaginosis, yeast vaginitis or urinary tract infections. These are common female diseases that lack appropriate medical solutions.

The product will now be distributed through the combined distribution networks of Chr. Hansen and BioGaia. Distributors are already in place in several markets and interest is at hand in a number of other countries.
Urex is continuing its clinical research in the field, which will lend further support to the marketing of the product.

"We are very pleased to be able to conclude this agreement with Urex and Chr. Hansen which allows us to add another very interesting indication area to our present ones" says Peter Rothschild, Managing director BioGaia.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish